Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

BMY

STRONG BUY

Bristol-Myers Squibb Company · Healthcare · United States · $117.5B · Avg Vol: $772M/d

99
StockRank
Get insider-trade alerts
Q
74
V
68
M
70
P/E (TTM)
16.1x
ROE
38.7%
D/E
2.3x
Dividend %
4.3%
Dir. Trades · 180d
−$1.9M →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases, primarily in oncology, immunology, cardiovascular, and hematology. Its strong research and development pipeline, coupled with a portfolio of blockbuster drugs and strategic acquisitions, provides a significant competitive moat in specialized therapeutic areas. BMY is a leading global biopharmaceutical firm known for its groundbreaking therapies and robust intellectual property portfolio.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue46.2B45.0B48.3B48.2B1.4%48.5B47.3B46.2B-2.1%
EPS2.973.88-4.413.475.3%3.593.563.490.3%
Shares2.9B2.9B2.9B2.9B+0.8%————
Debt40.7B41.5B51.2B47.1B5.0%46.4B———
Equity31.1B29.4B16.3B18.5B-15.9%————
Op CF13.1B13.9B15.2B14.2B2.7%13.3B———
Inv CF-1.1B-2.3B-21.4B-4.1B—————
Fin CF-17.0B-9.4B5.1B-10.3B—————
Loading 1Y...
PRICE (1Y)+0.7%
54.0055.1456.2857.4258.56May 27Jun 17Jul 9
SMA 50SMA 200
Close
$57.94
RSI (14)
61.1
52W High
$61.55
From 52W High
0.9%

SCORE BREAKDOWN

Quality
74
ROIC
16.8%88.4
ROE
38.7%95.8
GP/Assets
38.8%78.4
Op. Margin
33.0%94.3
FCF/Assets
10.9%88.7
Piotroski
999.1
Int. Cover
5.9x52.8
D/E Ratio
2.31x5.3
Current Ratio
1.42x23.8
Value
68
P/E (TTM)
16.1x70.5
EV/EBITDA
8.1x78.2
P/FCF
11.9x78.1
P/B
5.9x22.9
P/S
2.4x62.3
Div Yield
4.3%86.3
Momentum
70
52W High %
94%88.3
RS 6M
-0%70.4
SMA 50/200
1.06x77.0
EPS Rev 4W
+0.4%79.7
EPS Rev 12W
-1.3%29.2
EPS Improve
+72%64.3
Q Growth
9%50.0

FUNDAMENTALS

Market Cap
$117.5B
P/E (Forward)
9.4x
Gross Margin
72.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMY are excluded.

TickerCompanyMkt CapStockRankSignal
BMYBristol-Myers Squibb Company(you)$117.5B99STRONG BUY
SAN.PASanofi$102.3B97STRONG BUY
GSKGSK plc$105.2B95STRONG BUY
PFE.MXPfizer Inc.$137.8B95STRONG BUY
GIS.DEGilead Sciences, Inc.$157.4B97STRONG BUY
AMGN.MXAmgen Inc.$192.8B96STRONG BUY
NVON.MXNovo Nordisk A/S$212.5B90STRONG BUY
MRK.MXMerck & Co., Inc.$316.3B98STRONG BUY
ROP.SWRoche Holding AG$323.7B97STRONG BUY
BAYN.DEBayer Aktiengesellschaft$52.6B91STRONG BUY

Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 47.5%

Bristol-Myers Squibb Company (BMY) — Stock Score Summary

Bristol-Myers Squibb Company (BMY) has a MoatMap StockRank of 99/100 based on Quality (74/100), Value (68/100), and Momentum (70/100) factor scores. The current signal is STRONG BUY.

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases, primarily in oncology, immunology, cardiovascular, and hematology. Its strong research and development pipeline, coupled with a portfolio of blockbuster drugs and strategic acquisitions, provides a significant competitive moat in specialized therapeutic areas. BMY is a leading global biopharmaceutical firm known for its groundbreaking therapies and robust intellectual property portfolio.

Key Financial Metrics

Price$57.94
Market Cap$117.5B
P/E (TTM)16.14
P/E (Forward)9.36
Price/Book5.90
Return on Equity38.7%
Return on Invested Capital16.8%
Debt/Equity230.97
Gross Margin72.0%
Operating Margin33.0%
Revenue Growth2.6%
Dividend Yield4.3%
Free Cash Flow$9.9B

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bristol-Myers Squibb Company’s (BMY) StockRank?
MoatMap’s StockRank for Bristol-Myers Squibb Company (BMY) is 99/100, with a Strong Buy signal. It is a composite of Quality (74), Value (68), and Momentum (70) factor ranks across MoatMap’s 20,000+ stock universe.
Does Bristol-Myers Squibb Company have an economic moat?
Bristol-Myers Squibb Company (BMY) has a Quality factor score of 74/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bristol-Myers Squibb Company a buy, hold, or sell?
MoatMap’s current signal for Bristol-Myers Squibb Company (BMY) is Strong Buy, based on a StockRank of 99/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).
Browse all ranked stocksBMY deep dive reportAI ChampionsHow we score stocksSense-check another stock